Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth [Yahoo! Finance]
Evotec SE (EVO)
NASDAQ:AMEX Investor Relations:
eatonvance.com
Company Research
Source: Yahoo! Finance
EVOTEC’S REPORTING STRUCTURE WILL CHANGE TO BUSINESS SEGMENTS “SHARED R&D” AND “JUST - EVOTEC BIOLOGICS” STARTING Q1 2024 HAMBURG, GERMANY / ACCESSWIRE / April 24, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today reported financial results and corporate updates for the fiscal year ended 31 December 2023 and announced a priority reset to optimise its business to meet evolving market demand and focus on profitable growth in 2024 and beyond. CONTINUED GROWTH DESPITE MULTIPLE CHALLENGES Group revenues up 4% to € 781.4 m (+6% at constant fx rates (2022: € 751.4 m)) Revenues from Just - Evotec Biologics up 111% to € 108.4 m (2022: € 51.3 m) Base business excluding Just - Evotec Biologics down (4)%, including approx. (10)% impact as a result of the severe cyber-attack Gross margin of 22.6% (2022: 23.2%) despite low contribution from milestones and business disruption during Q2 2023 Adjusted Group E
Show less
Read more
Impact Snapshot
Event Time:
EVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVO alerts
High impacting Evotec SE news events
Weekly update
A roundup of the hottest topics
EVO
News
- Bayer and Evotec Collaborate to Advance Precision Cardiology [Yahoo! Finance]Yahoo! Finance
- Bayer and Evotec Collaborate to Advance Precision CardiologyAccesswire
- Evotec SE (NASDAQ:EVO) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Evotec SE (NASDAQ: EVO) had its price target lowered by analysts at HC Wainwright from $14.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Evotec: Still A Speculative Buy After A Significant Decline [Seeking Alpha]Seeking Alpha